
Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA
Description
About Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA
The Human Leucyl-cystinyl aminopeptidase Peptide (IEDB: 519996) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Leucyl-cystinyl aminopeptidase Peptide, H-KKYFAATQFEPLA-OH (Uniprot: Q9UIQ6 aa: 286-298) from JPT is produced under strict quality control and quality management.
Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA - Specifications
- Peptide sequence: H-KKYFAATQFEPLA-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Melanoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA
References:
Read References with JPT’s Antigen Peptides
Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA has been described in:
Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires., Immunogenetics, 2015 (PMID: 25502872)
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy., Oncoimmunology, 2018 (PMID: 29632711)
Documentation
Documentation for Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA
Properties
Properties of Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Leucyl-cystinyl aminopeptidase 286-298, KKYFAATQFEPLA
Information | Values |
---|---|
Sequence: | H-KKYFAATQFEPLA-OH |
Specifications: | 13mer peptide as TFA salt |